VTI ETF Update, October 8, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 08 2025
0mins
Should l Buy FBLG?
Source: TipRanks
VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.69% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.21% upside.
Holdings Analysis: VTI's top five holdings with the highest upside potential include Biodesix and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; overall, VTI's Smart Score indicates it will likely perform in line with the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBLG
Wall Street analysts forecast FBLG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.290
Low
1.50
Averages
3.25
High
5.00
Current: 1.290
Low
1.50
Averages
3.25
High
5.00
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FibroBiologics Reports Positive Results for Burn Treatment
- Preclinical Study Results: FibroBiologics' preclinical study using human dermal fibroblast spheroids for burn treatment demonstrated a significant reduction in inflammation, indicating the therapy's potential in improving burn healing.
- Gene Expression Changes: The study revealed a marked decrease in the expression of collagen synthesis-related genes (Col1a1 and Col3a1) and ECM turnover genes (Mmp1a and Mmp8) in the treatment group, suggesting the therapy may effectively inhibit excessive scarring.
- Immune Response Modulation: Post-treatment, a three-fold decrease in the pro-inflammatory marker interleukin IL-1B and a four-fold increase in the anti-inflammatory cytokine IL-10 were observed, showcasing the therapy's effectiveness in modulating immune responses.
- Market Reaction: Despite FibroBiologics' stock closing down 5.48% at $1.38 on Monday, these positive preclinical results may provide support for future market performance.
See More
FibroBiologics Releases First Batch of CYWC628 Drug for Clinical Trials
- Clinical Trial Launch: FibroBiologics has successfully released the first batch of its CYWC628 drug product, marking a significant milestone in its clinical trial for diabetic foot ulcers (DFUs), which is expected to provide new treatment options for millions of patients.
- FDA Compliance: The drug was manufactured in accordance with the U.S. FDA's current Good Manufacturing Practices (cGMP) and has passed all required safety and quality testing, ensuring its safety and efficacy for clinical use.
- R&D Platform Validation: The release of the first batch allows FibroBiologics to begin enrolling DFUs patients for its Phase 1/2 clinical trial, which will provide critical data for evaluating the safety, tolerability, and preliminary efficacy of CYWC628, further validating its fibroblast-based platform.
- Significant Market Potential: As an investigational therapy targeting DFUs, CYWC628 addresses a gap in the current market for effective long-term treatment options, which is expected to drive FibroBiologics' commercialization efforts in the biotechnology sector.
See More
FIBROBIOLOGICS UNVEILS CYWC628 DRUG FOR PHASE 1/2 CLINICAL TRIAL ON DIABETIC FOOT ULCERS
Announcement of Drug Release: FibroBiologics has announced the release of its new drug product, CYWC 628, aimed at treating Phase 1/2 diabetic foot ulcers.
Clinical Trial Focus: The drug will be utilized in clinical trials specifically designed to assess its effectiveness in managing diabetic foot ulcers.
See More
FibroBiologics Reports Q1 2026 Financial Results and Corporate Update
- Clinical Trial Progress: FibroBiologics has completed the manufacturing of the first two batches of the CYWC628 drug product in compliance with FDA cGMP, laying the groundwork for the phase 1/2 clinical trial for diabetic foot ulcers, with patient dosing expected to commence in Q2 2026.
- Positive Preclinical Results: The company reported promising preclinical outcomes in its burn program using proprietary fibroblast spheroid technology, indicating an increase in tissue repair cytokines and a significant reduction in inflammation drivers, suggesting strong therapeutic potential for future clinical applications.
- Funding and Compliance: FibroBiologics raised $3 million through a direct offering and secured an additional $2.5 million post-March 31, 2026, successfully regaining compliance with Nasdaq listing requirements, thereby enhancing the company's financial stability.
- Patent Portfolio Expansion: The company has expanded its patent portfolio with new patents covering fibroblast cell therapy for osteoporosis and a novel fibroblast-based treatment for cachexia, further solidifying its intellectual property in the biotechnology sector and supporting future product development.
See More
FibroBiologics Reports Q1 2026 Financial Results with $5M Loss
- Financial Loss Overview: FibroBiologics reported a net loss of approximately $5 million for the three months ended March 31, 2026, primarily due to increased research and development and administrative expenses, indicating ongoing investment in technology development amid financial pressure.
- Cash Flow Status: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, reflecting tight operational funding that may impact future research and operational capabilities.
- Financing Activities: After March 31, 2026, FibroBiologics raised approximately $2.5 million net through a registered direct offering, aimed at enhancing liquidity and supporting ongoing operations.
- Nasdaq Compliance: FibroBiologics successfully met Nasdaq's $2.5 million equity rule through a combined unit offering priced at $4.40 and a 1-for-20 reverse split, ensuring compliance in the capital markets.
See More
FibroBiologics Advances Phase 1/2 Clinical Trial for CYWC628
- Clinical Trial Launch: FibroBiologics is on track to dose the first patient with CYWC628 for diabetic foot ulcers in Q2 2026, marking a significant milestone in its clinical development and potentially enhancing its market position in chronic disease treatments.
- Manufacturing Compliance: The company has completed the production of the first two batches of CYWC628 in accordance with FDA Good Manufacturing Practices (cGMP), ensuring product quality and laying a solid foundation for the upcoming clinical trials.
- Financial Position Improvement: FibroBiologics raised $3 million through a direct offering in Q1 2026, bolstering its cash flow, and despite an increase in R&D expenses to $3 million, the company remains compliant, reflecting robust financial management.
- Patent Portfolio Expansion: The company has secured new patents for treatments targeting osteoporosis and cachexia, further strengthening its intellectual property in cell therapy, which is expected to provide significant support for future product development and market competitiveness.
See More
FibroBiologics Reports Positive Results for Burn Treatment
- Preclinical Study Results: FibroBiologics' preclinical study using human dermal fibroblast spheroids for burn treatment demonstrated a significant reduction in inflammation, indicating the therapy's potential in improving burn healing.
- Gene Expression Changes: The study revealed a marked decrease in the expression of collagen synthesis-related genes (Col1a1 and Col3a1) and ECM turnover genes (Mmp1a and Mmp8) in the treatment group, suggesting the therapy may effectively inhibit excessive scarring.
- Immune Response Modulation: Post-treatment, a three-fold decrease in the pro-inflammatory marker interleukin IL-1B and a four-fold increase in the anti-inflammatory cytokine IL-10 were observed, showcasing the therapy's effectiveness in modulating immune responses.
- Market Reaction: Despite FibroBiologics' stock closing down 5.48% at $1.38 on Monday, these positive preclinical results may provide support for future market performance.
See More
FibroBiologics Releases First Batch of CYWC628 Drug for Clinical Trials
- Clinical Trial Launch: FibroBiologics has successfully released the first batch of its CYWC628 drug product, marking a significant milestone in its clinical trial for diabetic foot ulcers (DFUs), which is expected to provide new treatment options for millions of patients.
- FDA Compliance: The drug was manufactured in accordance with the U.S. FDA's current Good Manufacturing Practices (cGMP) and has passed all required safety and quality testing, ensuring its safety and efficacy for clinical use.
- R&D Platform Validation: The release of the first batch allows FibroBiologics to begin enrolling DFUs patients for its Phase 1/2 clinical trial, which will provide critical data for evaluating the safety, tolerability, and preliminary efficacy of CYWC628, further validating its fibroblast-based platform.
- Significant Market Potential: As an investigational therapy targeting DFUs, CYWC628 addresses a gap in the current market for effective long-term treatment options, which is expected to drive FibroBiologics' commercialization efforts in the biotechnology sector.
See More
FIBROBIOLOGICS UNVEILS CYWC628 DRUG FOR PHASE 1/2 CLINICAL TRIAL ON DIABETIC FOOT ULCERS
Announcement of Drug Release: FibroBiologics has announced the release of its new drug product, CYWC 628, aimed at treating Phase 1/2 diabetic foot ulcers.
Clinical Trial Focus: The drug will be utilized in clinical trials specifically designed to assess its effectiveness in managing diabetic foot ulcers.
See More
FibroBiologics Reports Q1 2026 Financial Results and Corporate Update
- Clinical Trial Progress: FibroBiologics has completed the manufacturing of the first two batches of the CYWC628 drug product in compliance with FDA cGMP, laying the groundwork for the phase 1/2 clinical trial for diabetic foot ulcers, with patient dosing expected to commence in Q2 2026.
- Positive Preclinical Results: The company reported promising preclinical outcomes in its burn program using proprietary fibroblast spheroid technology, indicating an increase in tissue repair cytokines and a significant reduction in inflammation drivers, suggesting strong therapeutic potential for future clinical applications.
- Funding and Compliance: FibroBiologics raised $3 million through a direct offering and secured an additional $2.5 million post-March 31, 2026, successfully regaining compliance with Nasdaq listing requirements, thereby enhancing the company's financial stability.
- Patent Portfolio Expansion: The company has expanded its patent portfolio with new patents covering fibroblast cell therapy for osteoporosis and a novel fibroblast-based treatment for cachexia, further solidifying its intellectual property in the biotechnology sector and supporting future product development.
See More
FibroBiologics Reports Q1 2026 Financial Results with $5M Loss
- Financial Loss Overview: FibroBiologics reported a net loss of approximately $5 million for the three months ended March 31, 2026, primarily due to increased research and development and administrative expenses, indicating ongoing investment in technology development amid financial pressure.
- Cash Flow Status: As of March 31, 2026, the company had approximately $1.5 million in cash and cash equivalents, reflecting tight operational funding that may impact future research and operational capabilities.
- Financing Activities: After March 31, 2026, FibroBiologics raised approximately $2.5 million net through a registered direct offering, aimed at enhancing liquidity and supporting ongoing operations.
- Nasdaq Compliance: FibroBiologics successfully met Nasdaq's $2.5 million equity rule through a combined unit offering priced at $4.40 and a 1-for-20 reverse split, ensuring compliance in the capital markets.
See More
FibroBiologics Advances Phase 1/2 Clinical Trial for CYWC628
- Clinical Trial Launch: FibroBiologics is on track to dose the first patient with CYWC628 for diabetic foot ulcers in Q2 2026, marking a significant milestone in its clinical development and potentially enhancing its market position in chronic disease treatments.
- Manufacturing Compliance: The company has completed the production of the first two batches of CYWC628 in accordance with FDA Good Manufacturing Practices (cGMP), ensuring product quality and laying a solid foundation for the upcoming clinical trials.
- Financial Position Improvement: FibroBiologics raised $3 million through a direct offering in Q1 2026, bolstering its cash flow, and despite an increase in R&D expenses to $3 million, the company remains compliant, reflecting robust financial management.
- Patent Portfolio Expansion: The company has secured new patents for treatments targeting osteoporosis and cachexia, further strengthening its intellectual property in cell therapy, which is expected to provide significant support for future product development and market competitiveness.
See More
